Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 192-197

  O'Neal, Wesley T ^a   Soliman, Elsayed Z ^a   Howard, George ^b   Howard, Virginia J ^b   Safford, Monika M ^c   Cushman, Mary ^d   Zakai, Neil A ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Biological markers; Coronary disease

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; F8 PROTEIN, HUMAN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CLINICAL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOSTASIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOM SAMPLE; RISK FACTOR; STATISTICAL ANALYSIS; CEREBROVASCULAR ACCIDENT; COMPLICATION; CORONARY ARTERY DISEASE; ETHNIC GROUP; ETHNOLOGY; GEOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

AGED; ATRIAL FIBRILLATION; BIOMARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; ETHNIC GROUPS; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; GEOGRAPHY; HEMOSTASIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84941952876     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.09.009     Document Type: Article

References (40)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2-e220.
2. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285(18):2370-2375.
3. Goto S., Bhatt D.L., Rother J., et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am. Heart J. 2008, 156(5):855-863. 863 e852.
4. Conen D., Chae C.U., Glynn R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011, 305(20):2080-2087.
5. Soliman E.Z., Safford M.M., Muntner P., et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 2014, 174(1):107-114.
6. O'Neal W.T., Sangal K., Zhang Z.M., Soliman E.Z. Atrial fibrillation and incident myocardial infarction in the elderly. Clin. Cardiol. 2014, 37(12):750-755.
7. Soliman E.Z., Lopez F., O'Neal W.T., et al. Atrial fibrillation and risk of ST-segment elevation versus non-ST segment elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2015, 131(21):1843-1850.
8. Mahe I., Bergmann J.F., Chassany O., et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb. Res. 2012, 129(6):693-699.
9. Sadanaga T., Sadanaga M., Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J. Am. Coll. Cardiol. 2010, 55(20):2225-2231.
10. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb. Haemost. 2003, 90(6):1163-1172.
11. Lip G.Y., Patel J.V., Hughes E., Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007, 38(4):1229-1237.
12. Hermida J., Lopez F.L., Montes R., Matsushita K., Astor B.C., Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). Am. J. Cardiol. 2012, 109(1):95-99.
13. Kritchevsky S.B., Cesari M., Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc. Res. 2005, 66(2):265-275.
14. Howard V.J., Cushman M., Pulley L., et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005, 25(3):135-143.
15. Barlow W.E., Ichikawa L., Rosner D., Izumi S. Analysis of case-cohort designs. J. Clin. Epidemiol. 1999, 52(12):1165-1172.
16. Zakai N.A., Judd S.E., Alexander K., et al. ABO blood type and stroke risk: the REasons for Geographic And Racial Differences in Stroke study. J. Thromb. Haemost. 2014, 12(4):564-570.
17. Safford M.M., Brown T.M., Muntner P.M., et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA 2012, 308(17):1768-1774.
18. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation. 2007, 116(22):2634-2653.
19. Prineas R.J., Crow R.S., Blackburn H.W. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification 2010, Springer, London. second ed.
20. Gillett S.R., Boyle R.H., Zakai N.A., McClure L.A., Jenny N.S., Cushman M. Validating laboratory results in a national observational cohort study without field centers: the reasons for geographic and racial differences in stroke cohort. Clin. Biochem. 2014, 47(16-17):243-246.
21. Peralta C.A., Shlipak M.G., Judd S., et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011, 305(15):1545-1552.
22. Soliman E.Z., Howard G., Meschia J.F., et al. Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke 2011, 42(10):2950-2953.
23. Choudhury A., Lip G.Y. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol. Haemost. Thromb. 2003, 33(5-6):282-289.
24. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
25. Lip G.Y., Lowe G.D., Rumley A., Dunn F.G. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am. Heart J. 1996, 131(4):724-730.
26. Sadanaga T., Kohsaka S., Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology 2010, 117(1):31-36.
27. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart J. 2013, 34(20):1475-1480.
28. Nakatani Y., Mizumaki K., Nishida K., et al. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients. Circ. J. 2012, 76(2):317-321.
29. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361(12):1139-1151.
30. Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012, 125(5):669-676.
31. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365(10):883-891.
32. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011, 365(11):981-992.
33. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009, 361(24):2342-2352.
34. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014, 129(7):764-772.
35. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004, 350(14):1387-1397.
36. Danesh J., Whincup P., Walker M., et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001, 103(19):2323-2327.
37. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 1999, 19(3):493-498.
38. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
39. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108(24):3006-3010.
40. Hatzinikolaou-Kotsakou E., Tziakas D., Hotidis A., et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am. J. Cardiol. 2006, 97(5):659-661.